Company intelligence / Profile preview
Yuyao Biotech
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
Overview
Yuyao Biotech is a Shanghai-based biotech company founded in April 2020 that leverages artificial intelligence and modern drug discovery technologies to address major unmet needs in oncology and immune-related diseases. Its lead program YY001 is a small molecule antagonist of the prostaglandin E2 EP4 receptor currently in Phase 2 trials for stomach/gastric cancer as well as other solid tumors. The company has additional programs targeting STAT3 for hematological malignancies and other innovative targets; it collaborates with top academic institutions for translational research. Early clinical data show positive safety/tolerability results for YY001 with ongoing evaluation of efficacy endpoints.
- Therapeutic areas
- OncologyImmunologyNeurologyHematology
- Modalities
- Small moleculeMonoclonal antibodyMonoclonal antibody-drug conjugateGene-modified cell therapyFusion proteinCell therapyOncolytic virus therapySubunit vaccine
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Yuyao Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yuyao Biotech.